Angela Perry, MD
Ophthalmic Plastic and Reconstructive Surgery · Pasadena, CANPI 1063411858
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 80.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $5,937 and has fallen 97.8% since, to $132 in 2025.
Across 125 payments — averaging $67.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- AbbVie$361
- Bausch & Lomb, A Division Of Bausch Health US, LLC$162
- Tarsus Pharmaceuticals, Inc.$144
- Mallinckrodt Hospital Products Inc.$143
- Ocular Therapeutix, Inc.$131
- plus $712 from 11 others
What the payments were for
- Speaking & faculty fees$4,00047%
- Travel & lodging$1,05212%
- Food & beverage$3,40140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 73 | $6,800 |
| AbbVie(2 entities) | 13 | $361 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $162 |
| Tarsus Pharmaceuticals, Inc. | 2 | $144 |
| Mallinckrodt Hospital Products Inc. | 7 | $143 |
| Ocular Therapeutix, Inc. | 2 | $131 |
| Teva Pharmaceuticals USA, Inc. | 1 | $107 |
| Novartis | 5 | $107 |
| Revance Therapeutics, Inc. | 1 | $85 |
| Alcon | 3 | $79 |
| Kala Pharmaceuticals, Inc. | 3 | $71 |
| Sun Pharmaceutical Industries Inc. | 3 | $65 |
| Biotissue Holdings Inc. | 2 | $49 |
| Oyster Point Pharma, Inc. | 2 | $47 |
| Bausch & Lomb Americas Inc. | 2 | $47 |
| Aerie Pharmaceuticals, Inc. | 2 | $37 |
| Tactile Systems Technology Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,453 in reported general payments places this provider in the 75th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.
See all ophthalmic plastic and reconstructive surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 21 | $11,807 |
| ErythromycinErythromycin Base | 436 | $4,839 |
| MoxifloxacinMoxifloxacin Hcl | 86 | $2,301 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 89 | $847 |
| Ciprofloxacin Hcl | 65 | $701 |
| Methylprednisolone | 105 | $626 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $595 |
| Neomycin-Bacitracin-PolymyxinNeomycin/Bacitracin/Polymyxinb | 25 | $586 |
| Prednisolone Acetate | 14 | $579 |
| Doxycycline Hyclate | 17 | $414 |
| Latanoprost | 25 | $358 |
| Timolol Maleate | 15 | $219 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $135 |
| Cephalexin | 13 | $104 |
| Clindamycin Hcl | 12 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $361 | $11,80721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.
Other ophthalmic plastic and reconstructive surgery in Pasadena
- Marjan FaridIrvine$742K
- Jeffrey JosephNewport Beach$292K
- Sandy Zhang-NunesLos Angeles$149K
- Soheab UgradarLos Angeles$131K
- Andrea KosslerStanford$91K
- Nicolas BiroWest Covina$76K
- Joseph ChangBakersfield$74K
- Anupam JayaramMenlo Park$26K
- Charles KimStockton$21K
- Omar OzgurMission Viejo$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.